Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Decreases By 79.5%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a significant decrease in short interest in August. As of August 14th, there was short interest totaling 770 shares, a decrease of 79.5% from the July 30th total of 3,749 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily volume of 34,611 shares, the short-interest ratio is currently 0.0 days.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Friday, July 17th. Rodman & Renshaw began coverage on Bolt Biotherapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Bolt Biotherapeutics currently has a consensus rating of “Hold” and an average price target of $14.50.

Bolt Biotherapeutics Price Performance

NASDAQ BOLT opened at $3.79 on Wednesday. Bolt Biotherapeutics has a 1 year low of $3.13 and a 1 year high of $7.20. The company has a fifty day simple moving average of $3.91 and a 200 day simple moving average of $4.44. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 1.47. The company has a market cap of $7.29 million, a P/E ratio of -0.23 and a beta of 1.18.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, August 11th. The company reported ($4.57) EPS for the quarter, missing the consensus estimate of ($3.39) by ($1.18). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.50 million. Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%. On average, sell-side analysts predict that Bolt Biotherapeutics will post -11.1 EPS for the current year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several large investors have recently made changes to their positions in the business. Nan Fung Group Holdings Ltd bought a new stake in Bolt Biotherapeutics during the 2nd quarter valued at approximately $19,250,000. Renaissance Technologies LLC increased its position in Bolt Biotherapeutics by 40.3% in the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after buying an additional 22,200 shares during the period. T3 Companies LLC bought a new position in Bolt Biotherapeutics in the 4th quarter worth approximately $208,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Bolt Biotherapeutics during the fourth quarter worth approximately $112,000. Finally, Susquehanna International Group LLP acquired a new position in shares of Bolt Biotherapeutics during the third quarter worth approximately $89,000. Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.